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TaiwanBackground: Multiple antibiotic-resistant clones of Streptococcus pneumoniae have spread
throughout the world and continue to evolve under the selective pressure of antibiotics and
vaccines. The aim of this study is to assess the susceptibility of S. pneumoniae isolates and
to analyze the resistance trends in Taiwan.
Methods: Antimicrobial susceptibility tests were performed on 152 nonmeningeal isolates of
S. pneumoniae that were collected from 13 different hospitals around Taiwan from 2006e
2007. Tests were performed using the broth microdilution method according to recommenda-
tions of the Clinical and Laboratory Standards Institute.
Results: The minimal inhibitory concentrations (MIC50/MIC90) of penicillin, cefotaxime, vanco-
mycin, and moxifloxacin were 0.5/1.0, 0.25/1.0, 0.25/0.5, and 0.06/0.12 mg/mL, respectively.
The susceptibility rates of penicillin, cefotaxime, vancomycin, and moxifloxacin were 99.3%,
99.3%, 100%, and 98.7%, respectively. However, if the meningitis breakpoints were applied
to these nonmeningeal isolates, the susceptibility rates of penicillin and cefotaxime were
reduced to 18.4% and 76.3%, respectively. Compared with the findings from previous studies
in Taiwan, our results show that the percentage of S. pneumoniae isolates with a penicillin
MIC of 0.12e1.0 mg/mL increased from 43.3% in 1996e1997 to 73.7% in 2006e2007
(p < 0.001). The percentage of S. pneumoniae isolates with a cefotaxime MIC of 1.0 mg/mL
increased from 11.3% in 1996e1997 to 23.0% in 2006e2007 (p < 0.001). Regarding the serial
MIC intervals of the four antimicrobial agents, there was no significant difference between
bacteremic and nonbacteremic isolates.
Conclusion: Although nonmeningeal S. pneumoniae isolates remained susceptible to penicillin,
the proportion of isolates with a penicillin MIC of 0.12e1.0 mg/mL or cefotaxime MIC of
1.0 mg/mL increased during the past decade in Taiwan. The ever-increasing resistance of
S. pneumoniae has a great impact on the treatment of meningitis.
Copyright ª 2012, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.
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Penicillin-resistant Streptococcus pneumoniae (PRSP) was
first reported in the late 1960s.1 Subsequently, S. pneu-
moniae isolates with a higher levels of penicillin and
multidrug-resistance (MDR) were found in South Africa in
the late 1970s.2 Higher prevalence rates of PRSP were
reported in Europe and the USA in the 1990s.3 The overall
resistance to penicillin (minimal inhibitory concentrations
[MIC]  2.0 mg/mL) was 23% (range: 6e54%), with the
highest prevalence found in Spain and France (> 50%).3 A
report from the SENTRY Antimicrobial Surveillance Program
(1999e2003) showed that the incidence of penicillin resis-
tance (MIC  2.0 mg/mL) in S. pneumoniae was 14.7% in
Europe, 12.7% in Latin America, and 15.9% in North America.4
In North America, the prevalence of MDR S. pneumoniae
increased from 5.7% in 1999 to 6.3% in 2003.4 Clones of MDR
S. pneumoniae have now been discovered worldwide.5e7
The application of the new nonmeningeal breakpoints of
penicillin (by CLSI-M100-S18 in 2008) had a great impact on
susceptibility rates. Data from the SENTRY Antimicrobial
Surveillance Program in 2006 were assessed using these new
breakpoints.8 Using a penicillin susceptibility breakpoint of
0.06 mg/mL, only 68% of isolates are susceptible to peni-
cillin; in contrast, using a breakpoint of 2.0 mg/mL, 93% of
isolates are susceptible.8
The prevalence of penicillin-insusceptible S. pneumoniae
has been reported in Taiwan, with rates ranging from 56.4%
(43% isolates with MIC of 0.12e1.0 mg/mL and 13.1% with
MIC  2.0 mg/mL) in the late 1990s and 76.2% (50.7% with
MIC of 0.12e1.0 mg/mL and 25.5% with MIC  2.0 mg/mL) inthe early 2000s.9e11 International clones of MDR S. pneu-
moniae have been identified in Taiwan since 1998.12
The resistance patterns of S. pneumoniae continue to
evolve under the selective pressure of multiple factors
(such as the use of antimicrobial agents,13 clonal spread
among hosts,7 and vaccination).14,15 The aim of this study is
to assess the susceptibility of S. pneumoniae isolates,
analyze resistance trends in Taiwan, and discuss the impact
of revised nonmeningeal breakpoints recommended by the
CLSI M100-S18.Methods
S. pneumoniae isolates
One hundred and fifty-two unique isolates of S. pneumoniae
were collected from 13 different hospitals in Taiwan,
including nine medical centers (Buddhist Tzu Chi General
Hospital: 4 isolates; Shin Kong Wu Ho-Su Memorial Hospital:
17 isolates; National Taiwan University Hospital: 31
isolates; Far Eastern Memorial Hospital: 25 isolates;
Taichung Veterans General Hospital: 7 isolates; Chung Shan
Medical University Hospital: 14 isolates; Changhua Christian
Hospital: 9 isolates; Chi-Mei Hospital: 5 isolates; and
Kaohsiung Veterans General Hospital: 5 isolates) and four
local hospitals (Taipei Medical University Hospital: 7
isolates; Tungs’ Taichung MetroHarbor Hospital: 4 isolates;
Chiayi Christian Hospital: 11 isolates; and National Taiwan
University Hospital, Yun-Lin Branch: 13 isolates), from
2006e2007. The sources of isolates included blood (27.6%),
Antimicrobial susceptibility of S. pneumoniae 307sputum (47.3%), pus (18.4%), nasal discharge (4.6%), pleural
fluid (0.7%), ear swab (0.7%), and eye swab (0.7%).
Broth microdilution
Antimicrobial susceptibility was assessed by broth micro-
dilution according to the standard method approved by the
CLSI.16 The bacterial isolates were incubated overnight on
5% sheep blood agar plates. Inoculants were prepared from
the bacterial colonies that formed on the 5% sheep blood
agar plates, and then the colonies were suspended in 0.9%
saline with a turbidity equivalent of 0.5 McFarland units.
The suspension was further diluted within 15 minutes to
give a final inoculum density of 5  105 CFU/mL in each test
tube, containing 1.0 mL of antimicrobial agent that had
been diluted in Mueller-Hinton broth with 5% lysed sheep
blood. The following concentrations of penicillin
and cefotaxime were used: 4 mg/mL, 2 mg/mL, 1 mg/mL,
0.5 mg/mL, 0.25 mg/mL, 0.12 mg/mL, 0.06 mg/mL, 0.03 mg/
mL, and 0.01 mg/mL. The test tubes were incubated at 35C
in ambient air for 20e24 hours prior to determining MIC. S.
pneumoniae ATCC 49619 was used as the control strain. The
CLSI interpretive criteria17 for MICs are as follow: (1) for
nonmeningeal strains: penicillin susceptible:  2.0 mg/mL,
intermediate susceptibility: 4.0 mg/mL, resistant: 8.0 mg/
mL; cefotaxime susceptible:  1.0 mg/mL, intermediate
susceptibility: 2.0 mg/mL, resistant: 4.0 mg/mL; moxi-
floxacin susceptible:  1.0 mg/mL, intermediate suscepti-
bility: 2.0 mg/mL, resistant: 4.0 mg/mL; vancomycin
susceptible:  1.0 mg/mL; (2) for meningeal strains: peni-
cillin susceptible:  0.06 mg/mL, resistant: 0.12 mg/mL;
cefotaxime susceptible:  0.5 mg/mL, intermediate
susceptibility: 1.0 mg/mL, resistant: 2.0 mg/mL.
Statistical analysis
Analyses were performed by using the Statistical Package
for the Social Science (version 15.1; SPSS Inc, Chicago, IL,
USA) & SAS 9.1.3. The Kendall’s tau-c test was used for
comparisons of trends in the susceptibilities of S. pneu-
moniae isolates in Taiwan from 1996 to 2007, and the
Pearson’s chi-squared test was used for comparisons of the
susceptibilities of 42 bacteremic and 110 nonbacteremic S.
pneumoniae isolates. A difference was considered statisti-
cally significant if the two-tailed p-value <0.05.
Results
Susceptibility
The susceptibilities of the 152 S. pneumoniae isolates are
shown in Table 1. The MIC50 and MIC90 of penicillin, cefo-
taxime, vancomycin, and moxifloxacin were 0.5/1.0, 0.25/
1.0, 0.25/0.5, and 0.06/0.12 mg/mL, respectively. The
susceptibility rates of penicillin, cefotaxime, vancomycin,
and moxifloxacin were 99.3%, 99.3%, 100%, and 98.7%,
respectively.
Comparisons of the susceptibilities of the 152 S pneu-
monia isolates using nonmeningeal and meningeal break-
point criteria are shown in Table 1. According to the
meningeal breakpoint, the susceptibility rates of penicillinand cefotaxime were 18.4% and 76.3%, respectively, while
the resistance rates were 81.6% and 0.7%, respectively.
Cross-resistance between penicillin and cefotaxime
The cross-susceptibility and cross-resistance of penicillin
and cefotaxime were analyzed and the results are listed in
Table 2. The data generally show good categorical agree-
ment between the MICs of penicillin and cefotaxime.
However, there are some disagreements. For example,
there were 8 isolates with penicillin MICs between
0.12e1.0 mg/mL, but the cefotaxime MICs  0.06 mg/mL; 10
isolates with penicillin MIC 2.0 mg/mL were identified, but
their cefotaxime MICs were in the range of 0.12e1.0 mg/mL.
Trends in susceptibility
The susceptibility rates of the isolates in this study were
assessed and compared with the results of two previous
studies that were conducted in Taiwan.9,18 Table 3 lists the
changes in the susceptibility trends of S. pneumoniae
isolates in Taiwan from 1996e2007. The serial percentages
of S. pneumoniae isolates with penicillin MIC of
0.12e1.0 mg/mL were 43.3%, 38.7%, and 73.7%, respec-
tively, whereas the serial percentages of S. pneumoniae
isolates with penicillin MIC  2.0 mg/mL were 13.1%, 44.5%,
and 7.9%, respectively. The percentage of S. pneumoniae
isolates with penicillin MIC of 0.12e1.0 mg/mL increased
from 43.3% in 1996e1997 to 73.7% in 2006e2007
(p < 0.001). The serial percentages of S. pneumoniae
isolates with cefotaxime MIC of 1.0 mg/mL were 11.3%, 34.6
%, and 23.0%, respectively, while the serial percentages of
S. pneumoniae isolates with cefotaxime MIC  2.0 mg/mL
were 2.2%, 6.9%, and 0.7%, respectively. The percentage of
S. pneumoniae isolates with cefotaxime MIC of 1 mg/mL
increased from 11.3% in 1996e1997 to 23.0% in 2006e2007
(p < 0.001).
Comparisons of the susceptibilities of bacteremic
and nonbacteremic isolates
Comparisons of the susceptibilities of 42 bacteremic and
110 nonbacteremic S pneumonia isolates are shown in
Table 4. The susceptibilities of these isolates did not differ
significantly (pZ 0.798, 1, and 1 for penicillin, cefotaxime,
and moxifloxacin, respectively).
Discussion
Of the 152 isolates, only 1 isolate (0.7%) was resistant to
penicillin with an MIC of 4.0 mg/mL and only 1 isolate (0.7%)
was resistant to cefotaxime with an MIC of 4.0 mg/mL. S.
pneumoniae isolates with high resistance levels to
extended-spectrum cephalosporins have been reported in
the USA, the UK, Spain, and New Zealand since 1995.19e22
Extended-spectrum cephalosporin-resistant S. pneumo-
niae isolates from the USA appear to have emerged from
different clones.19A multidrug-resistant 19F clone of S.
pneumoniae with high-level cefotaxime resistance was
identified in New Zealand in 1997e1998.22 S. pneumoniae
isolates with high-level resistance to cephalosporin (1.4% of
Table 2 Cross-susceptibility and cross-resistance analyses of the MIC intervals of penicillin compared with the MIC intervals of
cefotaxime for 152 S. pneumoniae isolates
Isolates categorized by
penicillin MIC (n)
Number (%) of isolates classified by cefotaxime MIC
0.06 mg/mL 0.12e1.0 mg/mL 2.0 mg/mL
0.06 mg/mL (28) 25 (89.2) 3 (10.8) 0
0.12e1.0 mg/mL (112) 8 (7.1) 104 (92.9) 0
2.0 mg/mL (12) 1 (8.3) 10 (83.4) 1 (8.3)
Table 1 Antimicrobial susceptibilities of 152 S. pneumoniae isolates collected in Taiwan (2006e2007). The susceptibilities
were interpreted according to the recommendations of CLSI M100-S18
Antimicrobial
agents
Ranges of
MIC (mg/mL)
MIC (g/mL)a Susceptibility by nonmeningeal
breakpointb
Susceptibility by meningeal
breakpoint
MIC50 MIC90 %S %I %R %S %I %R
Penicillin G <0.01e4 0.5 1 99.3 0.7 0 18.4 d 81.6
Cefotaxime <0.01e4 0.25 1 99.3 0 0.7 76.3 23.0 0.7
Vancomycin <0.01e1 0.25 0.5 100 0 0 e e e
Moxifloxacin <0.01e2 0.06 0.12 98.7 1.3 0 e e e
a MIC50/90, MIC of an antimicrobial agent inhibiting 50% or 90% of isolates, respectively.
b %S, percent susceptible; %I, percent intermediate susceptible; %R, percent resistant.
308 C.-F. Li et al.364 isolates) were also reported in another Taiwanese study
in 2008.18 The genotypes of S. pneumoniae isolates with
high-level b-lactam resistance (penicillin MIC  4.0 mg/mL
and cefotaxime  2.0 mg/mL) were then analyzed by mul-
tilocus sequence typing,18 and three clones (Spain23F-1,
Taiwan19F-14, and Taiwan23F-15) were identified.
Determining the susceptibility breakpoint depends on
the desired microbiological, pharmacokinetic, and/or
pharmacodynamic clinical outcomes.8 An intravenously
administered 2 MU dose of penicillin every 4 hours would
have a 99% likelihood of achieving serum concentrations
greater than the MIC of 25% of the therapy interval when
treating an isolate with an MIC of 2.0 mg/mL.23 A meta-
analysis suggested that increased mortality is not associ-
ated with an penicillin MIC  2.0 mg/mL for pneumococcal
pneumonia.24 These data support a penicillin-susceptible
breakpoint 2.0 mg/mL for nonmeningeal isolates.17 In
this study, if the susceptibilities of all of the 152Table 3 Trends in the susceptibility of 152 S. pneumoniae isola
Antimicrobial agents MIC (mg/mL)
1996e1997a (n Z 550)
Penicillin 0.06 43.6
0.12e1.0 43.3
2.0 13.1
Cefotaxime 0.5 86.5
1.0 11.3
2.0 2.2
Moxifloxacin 1.0 d
2.0 d
4.0
Vancomycin 2.0 0
4.0 0
a,b,c Data adopted from references 9, 18, and this study, respectivelynonmeningeal isolates were interpreted with the former
penicillin-susceptible breakpoint 0.06 mg/mL,25 only
18.4% of isolates would be susceptible to penicillin. In
contrast, using the revised penicillin-susceptible breakpoint
2.0 mg/mL, 99.3% of isolates would be susceptible to
penicillin. Using this revised nonmeningeal breakpoint of
penicillin, the proportion of isolates susceptible to peni-
cillin would be comparable with the proportion of isolates
susceptible to the nonmeningeal breakpoint of cefotaxime
(99.3%). In the USA from 2005e2006, the three surveillance
networks (SENTRY, PROTEKT, and ABCs surveillance)
reported that the susceptibility increased by approximately
25%, using the revised penicillin-susceptible breakpoint
2.0 mg/mL for nonmeningeal infections.8
The susceptibility of these nonmeningeal S. pneumoniae
isolates remained high enough for the treatment of non-
meningeal infections. S. pneumoniae, though isolated from
nonmeningeal sources, is also a potential pathogen oftes in Taiwan (1996e2007)
% of non-susceptible isolates
2003e2006b (n Z 364) 2006e2007c (n Z 152) p
16.8 18.4 <0.001
38.7 73.7
44.5 7.9
58.5 76.3 <0.001
34.6 23.0
6.9 0.7
99.5 98.7 0.443
0.2 1.3
0.3 0
0 0 d
0 0 d
.
Table 4 Comparison of the susceptibilities of 42 bacteremic and 110 nonbacteremic S. pneumoniae isolates
Antimicrobial agents MIC (mg/mL) Bacteremic isolates n (%) Non-bacteremic isolates n (%) p
Penicillin 0.06 9 (21.4) 26 (23.6) 0.798
0.12e1.0 31 (73.8) 76 (69.1)
2.0 2 (4.8) 8 (7.3)
Cefotaxime  1.0 42 (100.0) 109 (99.1) 1.000
2.0 0 (0.0) 0 (0.0)
4.0 0 (0.0) 1 (0.9)
Moxifloxacin 1.0 42 (100.0) 108 (98.2) 1.000
2.0 0 (0.0) 2 (1.8)
4.0 0 (0.0) 0 (0.0)
Vancomycin 1.0 42 (100.0) 110 (100.0) d
2.0 0 (0.0) 0 (0.0)
4.0 0 (0.0) 0 (0.0)
Antimicrobial susceptibility of S. pneumoniae 309meningitis. If the revised CLSI breakpoints for meningitis are
applied to these nonmeningeal isolates, there will be a very
dramatic impact on the susceptibility of S. pneumoniae to
penicillin and cefotaxime. Resistance rates will be much
higher if meningeal breakpoints are applied to these non-
meningeal isolates. The following results are likely: only
18.4% of isolates will be susceptible to penicillin and 76.3%
will be susceptible, 23% will be intermediately susceptible,
and 0.7% will be resistant to cefotaxime. Categorical
disagreement between the MICs of penicillin and cefotax-
ime was found in 22 isolates. This could be explained by
alterations in penicillin-binding proteins that could result in
different binding affinities for different b-lactams, e.g.,
penicillin and cefotaxime.26
Although 99.3% of the isolates were susceptible to
penicillin using the nonmeningeal breakpoint, the
percentage of S. pneumoniae isolates with penicillin MIC of
0.12e1.0 mg/mL increased from 43.3% (during the period of
1996e1997) to 73.7% (during the period of 2006e2007)
(p < 0.001). The percentage of S. pneumoniae isolates with
penicillin MIC of 2.0 mg/mL decreased from 13.1% (during
the period of 1996e1997) to 7.9% (during the period of
2006e2007) (p < 0.001). Interpreting susceptibility by
looking at just susceptibility or resistance will often mask
changes in the MIC distribution and changes in resistance
trends. Monitoring detailed MIC data is important for
epidemiology studies and determining appropriate treat-
ment strategies.
Regarding the serial MIC intervals of the four antimi-
crobial agents, there were no significant differences
between bacteremic and nonbacteremic isolates. Only
some major clones of antibiotic-resistant S. pneumoniae
were found to be spreading in Taiwan; for example,
Taiwan-23F, Taiwan-19F, Spanish-23F, Spanish-6B, Spanish-
9 V, ST320 (19A), and ST902 (6A).12,27 The most prevalent
serotypes of invasive isolates also were attributed to these
serotypes.10,27 Therefore, the diversity of resistance
patterns is limited.
In conclusion, although nonmeningeal S. pneumoniae
isolates remain susceptible to penicillin, the proportion of
isolates with a penicillin MIC of 0.12e1.0 mg/mL or cefo-
taxime MIC of 1.0 mg/mL has increased during the past
decade in Taiwan. The ever-increasing resistance of S.
pneumoniae has a great impact on the treatment of
meningitis.Acknowledgments
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